Biography

Dr. Hanan S. Anbar, Ph.D., earned her Ph.D. in Pharmaceutical Sciences (Pharmacology and Toxicology) from the Faculty of Pharmacy, Mansoura University, Egypt, in 2017. She is currently an an Associate Dean, Research Chair, Institutional Review Board, Associate Professor of Pharmacology and Toxicology at College of Pharmacy of Pharmacology and Toxicology at Dubai Pharmacy College for Girls, Dubai, United Arab Emirates. Dr. Anbar has authored over 44 publications in highly reputed international peer-reviewed journals. Her H-index is 16. She has presented her work at numerous international conferences. She has also served as a peer reviewer for several prestigious journals and has collaborated with prominent researchers from the USA, UK, Pakistan, UAE, Egypt, and the Republic of Korea.

Education

• Ph.D. in Pharmaceutical Sciences (Pharmacology and Toxicology), Mansoura University, Egypt, 2017

Research Interests

• Cancer
• Inflammation
• Hormonal Disturbance
• Endocrinal Disorders
• Neurodegenerative diseases

Research Publications

• Khoder, G. A. K., Mustafa, E. M., Zaib, S., Zein, R. A., & El-Gamal, M. I. (2026). Novel indole-based sulfonate and sulfamate derivatives as potent and selective urease inhibitors targeting Helicobacter pylori: A promising therapeutic strategy. Gut Pathogens, 18(1), 27.
• Ravi, A., Foster, P. A., Zaraei, S. O., Alhalaweh, A., & El-Gamal, M. I. (2026). Design and synthesis of novel piperazine-based sulfamate derivatives as steroid sulfatase inhibitors. Bioorganic Chemistry, 175, 109766.
• Anbar, H. S., Radi, A. W., Shaker, H. A., Omar, H. A., & El-Gamal, R. (2025). Protective potential of Irosustat, STX140 and the sulfonate derivative 1G in counteracting cisplatin-induced renal and hepatic toxicities: An in vivo comparative study. Life Sciences, 378, 123793.
• Ravi, A., Zaib, S., Zahra, S., El-Gamal, M. I., & Anbar, H. S. (2025). Synthesis, in vitro and in vivo evaluation, and computational modeling analysis of thioxothiazolidine derivatives as highly potent and selective $\alpha$-amylase inhibitors. European Journal of Medicinal Chemistry, 291, 117584.
• Anbar, H. S., Shehab, N. G., Yasin, A., El-Rouby, N. M. M., & Shahiwala, A. F. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLoS ONE, 19(9), e0308879.
• Sebastian, A., Abu Rabah, R. R., Zaraei, S. O., Al-Tel, T. H., & El-Gamal, M. I. (2024). Design, synthesis, biological evaluation, and in silico studies of novel pyridopyridine derivatives as anticancer candidates targeting FMS kinase. European Journal of Medicinal Chemistry, 274, 116557.
• Hashem, O., Zaib, S., Zaraei, S. O., El-Gamal, M. I., & Khoder, G. A. K. (2024). Design and discovery of urease and Helicobacter pylori inhibitors based on benzofuran/benzothiophene-sulfonate and sulfamate scaffolds for the treatment of ureolytic bacterial infections. International Journal of Biological Macromolecules, 271, 132502.
• Zaraei, S. O., Dohle, W., Anbar, H. S., Potter, B. V. L., & El-Gamal, M. I. (2024). Synthesis, biological evaluation, and stability studies of raloxifene mono- and bis-sulfamates as dual-targeting agents. Bioorganic and Medicinal Chemistry, 101, 117645.
• Alblooshi, A. J., Baig, M. R., & Anbar, H. S. (2024). Patients’ knowledge and pharmacists’ practice regarding the long-term side effects of proton pump inhibitors: A cross-sectional study. Archives of Academic Emergency Medicine, 12(1), e35.
• Alomar, T., Baig, M. R., & Anbar, H. S. (2024). Post COVID vaccination experience among the United Arab Emirates general public. Journal of Chemical Health Risks, 14(2), 319–329.
• Anbar, H. S., Vahora, N. Y., Shah, H. L., Potter, B. V. L., & El-Gamal, M. I. (2023). Promising drug candidates for the treatment of polycystic ovary syndrome (PCOS) as alternatives to the classical medication metformin. European Journal of Pharmacology, 960, 176119.
• El-Gamal, R., Elfarrash, S., El-Nablaway, M., Shoma, A. M., & El-Gamal, M. I. (2023). Anti-proliferative activity of RIHMS-Qi-23 against MCF-7 breast cancer cell line is through inhibition of cell proliferation and senescence but not inhibition of targeted kinases. BMC Cancer, 23(1), 1053.
• Jairoun, S. A., Alkhalidi, D. K., Jairoun, A. A., & Anbar, H. S. (2023). Over-the-counter antibiotic dispensing: Knowledge and practice of community pharmacists in the United Arab Emirates. Journal of Pharmaceutical Health Services Research, 14(3), 333–342.
• Anbar, H. S., Shehatou, G. S. G., Abdel-Rahim, M., Suddek, G. M., & Gameil, N. M. (2023). Evaluation of regression of diabetes-induced nephropathy and vascular dysfunction in rats by Montelukast via antioxidative and anti-inflammatory actions. Journal of Applied Pharmaceutical Science, 13(8), 167–176.
• Shahin, A. I., Zaib, S., Zaraei, S. O., Khoder, G. A. K., & El-Gamal, M. I. (2023). Design and synthesis of novel anti-urease imidazothiazole derivatives with promising antibacterial activity against Helicobacter pylori. PLoS ONE, 18(6), e0286684.
• Siddiqui, R. B., Rawas-Qalaji, M. M., El-Gamal, M. I., Potter, B. V. L., & Khan, N. A. (2023). Novel anti-acanthamoebic activities of Irosustat and STX140 and their nanoformulations. Antibiotics, 12(3), 561.
• Shahin, A. I., Zaraei, S. O., AlKubaisi, B. O., Al-Tel, T. H., & El-Gamal, M. I. (2023). Design and synthesis of new adamantyl derivatives as promising antiproliferative agents. European Journal of Medicinal Chemistry, 246, 114958.
• Rafiee, M. H., Abdul Rasool, B. K., Haider, M. A., & Anbar, H. S. (2023). Oral pioglitazone HCl-loaded solid lipid microparticles: Formulation design and bioactivity studies. Journal of Applied Pharmaceutical Science, 13(2), 161–174.
• Sultan, S., Zenati, R. A., Anbar, H. S., El-Gamal, M. I., & Semreen, M. H. (2025). Recent advances of quinoline-based small molecules as kinase inhibitors (2020–2024). ChemMedChem, 20(14), e202500279.
• Mustafa, E. M., Shahin, A. I., Alrashed, A. S., Anbar, H. S., & El-Gamal, M. I. (2024). An overview of the latest outlook of sulfamate derivatives as anticancer candidates (2020–2024). Archiv der Pharmazie, 357(10), e2400331.